Opus Genetics (IRD) Notes Payables (2019 - 2025)

Opus Genetics (IRD) posted quarterly Notes Payables of $21.3 million for Q3 2025, up 80.72% quarter-over-quarter from $11.8 million in Q2 2025.

Opus Genetics (IRD) Notes Payables (2019 - 2025) Analysis & Trends

Opus Genetics (IRD) has reported Notes Payables for 5 consecutive years, with $21.3 million the latest figure, recorded in Q3 2025.

In Q3 2025, Notes Payables changed N/A year-over-year to $21.3 million; the TTM figure through Sep 2025 stood at $21.3 million (changed N/A YoY), while the FY2024 annual figure was $2.0 million, up 2602.7% from the prior year.
Notes Payables rose to $21.3 million in Q3 2025 per IRD's latest filing, from $11.8 million in the prior quarter.
Across five years, Notes Payables topped out at $21.3 million in Q3 2025 and bottomed at $74000.0 in Q4 2023.
Historically, Notes Payables has averaged $5.4 million across 4 years, with a median of $215000.0 in 2022.
Annual changes were most pronounced in 2024 — Notes Payables jumped 2602.7% — and 2025, when it surged 17082.43%.
Opus Genetics' Notes Payables stood at $215000.0 in 2022, then tumbled by 65.58% to $74000.0 in 2023, then soared by 2602.7% to $2.0 million in 2024, then surged by 966.25% to $21.3 million in 2025.
Business Quant data shows IRD's Notes Payables at $21.3 million in Q3 2025, $11.8 million in Q2 2025, and $12.7 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Opus Genetics	298.36 Mn	209.55 Mn	-

Download Data